You are subscribed to the Formulary News Capsule.

Formulary

Print Subscribe

Digital Edition Subscribe

February 22, 2013

Web Version  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

Today's Headlines

FDA approves everolimus

FDA has approved everolimus (Zortress, Novartis) for the prophylaxis of organ rejection in adult patients receiving a liver transplant. » Full article

Patient adherence in clinical trials

In the last 10 years, many patients have developed unexpected toxicities from prescription drugs that have been on the market for 5 to 10 years, according to the Consumer Health Information Corp. » Full article

Effect of corticosteroid shot for tennis elbow

A single corticosteroid injection to treat unilateral lateral epicondylalgia—tennis elbow—is linked to poorer outcomes after 1 year, according to a study published February 6 in JAMA.
» Full article

Autism risk lowered with folic acid

A study by Norwegian researchers has shown that the use of folic acid supplements around the time of conception may lower the risk of autism in children. The study was published in the February 13, 2013, issue of The Journal of the American Medical Association.
» Full article

ADVERTISEMENT

Download Case Study: Reduce Rx Costs and Improve Member Health
Denying high-priced Rx claims may contain costs in the short term, but this practice can lead to poor adherence and complications for patients. Download this case study to learn how health plans can reduce drug spend with more affordable medication alternatives and provider and member education.

CONTINUING EDUCATION

New CPE Series: February activity available now

Welcome to the sixth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The February activity covers psychosocial considerations in the management of diabetes.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

EDITOR'S PICK

Antimicrobial stewardship programs-A review for the formulary decision-maker

The spread of antimicrobial resistance, lack of novel antimicrobial agents in development, and challenges to the drug discovery process are of significant global concern today. The state of this crisis is emphasized by published literature denoting the need for action on multiple levels as we move toward a second pre-antibiotic era or post-antibiotic era. Antimicrobial Stewardship Programs have become a particular area of focus as healthcare practitioners aim to combat these issues within institutions. In 2007 the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America published guidelines for developing an institutional program to enhance antimicrobial stewardship.
» Full article

 

Related Articles

Liver injury risk with tolvaptan

Adherence efforts are quantifiable

Osteoarthritis knee pain

Tocolytic therapy for preterm delivery

RESOURCES

Drug Watch

Latest Clinical News

SURVEY

What tops your priority list for 2013?

– Medication therapy management
– Pharmacy support for new models of care
– Specialty pharmacy management
– Advanced IT support to drive enhanced pharmacy programming

Respond Here
See what your colleagues are saying!

What can Formulary do for you?

Take our super short survey TODAY! http://www.surveygizmo.com/s3/1050662/Formulary-Readers

 
Powered by Modern Medicine Advanstar Medical Communications Group